Real-World Outcomes of Carotid Artery Stenting in Symptomatic and Asymptomatic Patients With Carotid Artery Stenosis

无症状的 医学 狭窄 心脏病学 颈动脉 内科学 放射科 动脉
作者
Kazutaka Uchida,Fumihiro Sakakibara,Nobuyuki Sakai,Koji Iihara,Hirotoshi Imamura,Akira Ishii,Yuji Matsumaru,Chiaki Sakai,Tetsu Satow,Kiyofumi Yamada,Manabu Shirakawa,Shinichi Yoshimura
出处
期刊:Jacc-cardiovascular Interventions [Elsevier BV]
卷期号:17 (9): 1148-1159 被引量:6
标识
DOI:10.1016/j.jcin.2024.03.014
摘要

The effectiveness and safety of carotid artery stenting (CAS) are comparable to those of carotid endarterectomy in both symptomatic and asymptomatic patients with carotid artery stenosis, but real-world outcomes are not well-known. The purpose of this study was to investigate the real-world clinical outcomes of CAS in symptomatic and asymptomatic patients with carotid artery stenosis. We conducted a nationwide retrospective registry study of 156 centers between January 2015 and December 2019. We enrolled consecutive patients with CAS managed by certified specialists from the Japanese Society of Neuroendovascular Therapy. Outcomes between symptomatic and asymptomatic patients were compared. The primary outcome was a composite of ischemic stroke and all-cause death at 30 days after CAS. Secondary outcomes were ischemic stroke, all-cause death, intracranial hemorrhage (ICH), and procedural complications. We analyzed 9,792 patients (symptomatic, n = 5,351; asymptomatic, n = 4,441). The mean age was 73.5 years, and men were dominant (86.4%). Embolism protection devices were used in 99% of patients. The primary outcome was not significantly different between the symptomatic and asymptomatic groups (120 [2.2%] vs 65 [1.5%]; adjusted OR: 1.30; 95% CI: 0.92-1.83). The incidences of symptomatic ICH, any ICH, acute in-stent occlusion, and hyperperfusion syndrome were significantly more prevalent in the symptomatic group (47 [0.9%] vs 8 [0.2%], aOR: 4.41 [95% CI: 1.68-11.6]; 73 [1.4%] vs 12 [0.3%], aOR: 3.56 [95% CI: 1.71-7.39]; 45 [0.8%] vs 19 [0.4%], aOR: 2.18 [95% CI: 1.08-4.40]; and 102 [1.9%] vs 36 [0.8%], aOR: 1.78 [95% CI: 1.17-2.71], respectively). Other secondary outcomes were not significantly different between the 2 groups. The complication rate after specialist-involved CAS at 30 days was low in real-world practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
恋空完成签到 ,获得积分10
刚刚
ylwu2018完成签到,获得积分10
刚刚
可可完成签到,获得积分10
刚刚
王致远发布了新的文献求助10
1秒前
2秒前
可爱的大白菜真实的钥匙完成签到 ,获得积分10
2秒前
2秒前
重要的雪莲完成签到 ,获得积分10
3秒前
3秒前
am发布了新的文献求助10
4秒前
4秒前
hooke发布了新的文献求助10
4秒前
superbanggg发布了新的文献求助200
4秒前
土豆··发布了新的文献求助10
4秒前
小王同志发布了新的文献求助20
4秒前
零下负七完成签到,获得积分10
4秒前
量子星尘发布了新的文献求助10
5秒前
丘比特应助机灵似狮采纳,获得10
5秒前
View完成签到,获得积分10
5秒前
6秒前
上善若水发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
qs5473完成签到,获得积分10
7秒前
View发布了新的文献求助10
8秒前
fei完成签到,获得积分10
8秒前
Emma应助科研通管家采纳,获得10
8秒前
肖肖肖完成签到 ,获得积分10
8秒前
丘比特应助科研通管家采纳,获得10
8秒前
无花果应助科研通管家采纳,获得10
8秒前
李爱国应助科研通管家采纳,获得10
8秒前
8秒前
JamesPei应助科研張采纳,获得30
8秒前
天天快乐应助科研通管家采纳,获得10
8秒前
打打应助科研通管家采纳,获得10
8秒前
呆橘完成签到 ,获得积分10
8秒前
起朱楼应助科研通管家采纳,获得10
8秒前
你好世界完成签到,获得积分10
8秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958299
求助须知:如何正确求助?哪些是违规求助? 3504528
关于积分的说明 11118735
捐赠科研通 3235777
什么是DOI,文献DOI怎么找? 1788506
邀请新用户注册赠送积分活动 871225
科研通“疑难数据库(出版商)”最低求助积分说明 802600